ES2647618T3 - Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel - Google Patents

Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel Download PDF

Info

Publication number
ES2647618T3
ES2647618T3 ES12165557.5T ES12165557T ES2647618T3 ES 2647618 T3 ES2647618 T3 ES 2647618T3 ES 12165557 T ES12165557 T ES 12165557T ES 2647618 T3 ES2647618 T3 ES 2647618T3
Authority
ES
Spain
Prior art keywords
dermatitis
inflammatory skin
pharmaceutically acceptable
formulations
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12165557.5T
Other languages
English (en)
Inventor
Jack A. Dejovin
Thomas M. Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Pharma SA
Original Assignee
Galderma Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Galderma Pharma SA filed Critical Galderma Pharma SA
Application granted granted Critical
Publication of ES2647618T3 publication Critical patent/ES2647618T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composición, que comprende: como mínimo un agonista del receptor adrenérgico a2 y una sal farmacéuticamente aceptable del mismo; y un vehículo farmacéuticamente aceptable; para utilización en el tratamiento de un trastorno inflamatorio de la piel y los síntomas asociados con él, en la que dicha composición se aplicará por vía tópica directamente a la zona afectada de piel de un paciente que necesita dicho tratamiento, en la que el, como mínimo, uno de un agonista del receptor adrenérgico a2 y una sal farmacéuticamente aceptable del mismo se selecciona del grupo que comprende nafazolina y xilometazolina, y en la que dicho trastorno inflamatorio de la piel es dermatitis, incluyendo dermatitis de contacto, dermatitis atópica, dermatitis seborreica, dermatitis numular, dermatitis exfoliativa generalizada, dermatitis de estasis y liquen simple crónico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES12165557.5T 2004-05-25 2005-05-25 Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel Active ES2647618T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US574142P 2004-05-25
US853585 2004-05-25

Publications (1)

Publication Number Publication Date
ES2647618T3 true ES2647618T3 (es) 2017-12-22

Family

ID=35451386

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05754754T Active ES2424644T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
ES12165557.5T Active ES2647618T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES05754754T Active ES2424644T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel

Country Status (15)

Country Link
EP (2) EP1761266B1 (es)
JP (2) JP4955543B2 (es)
KR (1) KR101257046B1 (es)
CN (2) CN101426502A (es)
AU (1) AU2005247467B2 (es)
BR (1) BRPI0511519A (es)
CA (2) CA2824612C (es)
DK (1) DK1761266T3 (es)
ES (2) ES2424644T3 (es)
MX (1) MXPA06013649A (es)
NZ (1) NZ552325A (es)
PL (1) PL1761266T3 (es)
PT (1) PT1761266E (es)
SI (1) SI1761266T1 (es)
WO (1) WO2005115395A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2011053487A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
EP2552448B1 (en) 2010-03-26 2019-04-24 Galderma Research & Development Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
SG189896A1 (en) * 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
WO2012052478A2 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
KR20210080591A (ko) * 2010-11-16 2021-06-30 알러간, 인코포레이티드 (3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐)메탄올을 포함하는 약제학적 조성물
BR112013020770A2 (pt) * 2011-02-15 2019-08-27 Allergan Inc composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
CN103889417A (zh) * 2011-10-19 2014-06-25 高德美国际公司 减少与全身使用5型磷酸二脂酶抑制剂有关的面部潮红的方法
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
SG11201509173WA (en) * 2013-05-06 2015-12-30 Allergan Inc Alpha adrenergic agonists for in the treatment of tissue trauma
AU2014292879A1 (en) * 2013-07-26 2016-02-11 Galderma Research & Development Compositions for treating skin thickening
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
WO2017007910A1 (en) 2015-07-09 2017-01-12 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
WO2020232020A1 (en) * 2019-05-14 2020-11-19 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
NZ504707A (en) * 1997-11-24 2002-11-26 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (es) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
EP1761266A2 (en) 2007-03-14
KR101257046B1 (ko) 2013-04-22
PT1761266E (pt) 2013-06-04
JP2008500356A (ja) 2008-01-10
DK1761266T3 (da) 2013-08-05
WO2005115395A3 (en) 2009-04-09
NZ552325A (en) 2010-11-26
SI1761266T1 (sl) 2013-08-30
PL1761266T3 (pl) 2013-09-30
WO2005115395A2 (en) 2005-12-08
CA2567401C (en) 2013-11-12
JP4955543B2 (ja) 2012-06-20
AU2005247467A1 (en) 2005-12-08
CA2824612A1 (en) 2005-12-08
EP2481412A1 (en) 2012-08-01
CA2824612C (en) 2016-08-16
CN101426502A (zh) 2009-05-06
EP2481412B1 (en) 2017-09-27
JP2012072176A (ja) 2012-04-12
BRPI0511519A (pt) 2007-12-26
CA2567401A1 (en) 2005-12-08
JP5547705B2 (ja) 2014-07-16
KR20070032716A (ko) 2007-03-22
ES2424644T3 (es) 2013-10-07
EP1761266A4 (en) 2009-11-11
MXPA06013649A (es) 2007-07-09
CN104490884A (zh) 2015-04-08
EP1761266B1 (en) 2013-05-08
AU2005247467B2 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
ES2647618T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
ES2532527T3 (es) Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
HN2008001144A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
BRPI0612072A2 (pt) inibidores da aspartil protease
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
CL2007003137A1 (es) Metodo para purificar aceites que comprende poner dicho aceite en contacto con agentes adsorbentes y filtracion en membrana; uso de un agente adsorbente o absorbente; y uso del aceite purificado.
PE20131341A1 (es) Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
BR112016009515A8 (pt) derivado de sulfonamida, composição farmacêutica, agente terapêutico ou um agente preventivo para doença inflamatória, e, inibidor de integrina a4ß7.
BR112015002249A2 (pt) composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
TNSN06234A1 (en) Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
ATE532313T1 (de) Ausfallsicheres system zum verwalten von client- server-kommunikation
ECSP088398A (es) Compuestos tricíclicos útiles como agonistas de receptores de oxitocina
AR065034A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
CL2007001779A1 (es) Compuestos triciclicos, con afinidad superior por los receptores de melatonina; composicion farmaceutica; util para la profilaxis o tratamiento de la enfermedad del sueno y compuestos intermediarios.
ES2543836T3 (es) Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.